GlaxoSmithKline Plans to Develop Better Drugs to Fight Cancer

GlaxoSmithKline Plans to Develop Better Drugs to Fight CancerMaking use of the new technology form British biotech company Immunocore, GlaxoSmithKline (GSK) is now preparing to develop better drugs to fight cancer in a better way.

It is learnt that GSK is keen to develop the new drugs that are capable of fighting tumors in new ways unlike antibody-based drugs. It was revealed on Tuesday that GSK will pay over 142 million pounds to Immunocore in pre-clinical milestone payments to access its work on multiple drug targets.

Further, the Oxford-based company will get around 200 million pounds for every product that will reach market. The company relies on a new type of medicines that it calls ImmTACs. These drugs make the use of T cell receptors to identify the changes occurring inside cells during cancer or viral infection.

These drugs then activate the immune system to kill the target cells. The conventional drugs used for the treatment only recognize the changes on surface cells. ImmTACs had a lot of capability of treating cancer. IMCgp100, the most advanced ImmTAC drugs developed to treat melanoma is said to be early Phase I/II clinical trials.

The company has been working on the technology for more than a decade. Under the new plans, biotech will be used to conduct the preclinical and early-stage trial work.